Eisai

Perfil de la empresa

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Descripción disponible en inglés.

Datos societarios

Sector

Salud

Industria

Drug Manufacturers - Specialty & Generic

País

Japón

Sede

4-6-10 Koishikawa, 112-8088, Tokyo

Empleados

10.543

Cotización

4523 · TSE

Índices

Nikkei 225

Divisa

JPY

ISIN

JP3160400002

Sitio web

eisai.co.jp